Business Wire

StrategyBlocks 6 Launches, Simplifying Ideation for Strategic Planning

19.4.2023 15:00:00 EEST | Business Wire | Press release

Share

StrategyBlocks, the leading cloud-based solution for strategic planning, portfolio management and execution, today announced the latest release of its enterprise strategic management platform, StrategyBlocks 6 (SB6). In addition to an overhaul of its interface and a redesigned homepage that offers greater clarity and ease of use, SB6 includes a new, proprietary ideation feature. StrategyBlocks Ideas helps organizations facilitate greater engagement across the team, making it easier to harness recommendations, proposals and opportunities at every level. As the premier solution in strategic software, StrategyBlocks 6 has been purposefully designed to address the common concerns facing organizations of every size, including how best to communicate, execute and track strategy, how to effectively generate reports for the executive team and board, and how to navigate changes within the organization through the lens of strategic planning and execution.

“Creating and evaluating a company’s strategy is no longer just an annual process, it requires ongoing effort,” said Craig Catley, managing director, StrategyBlocks. “Organizations require an evolution in the way they manage strategic planning, and SB6 was thoughtfully designed to provide real-time insights into strategic performance. With a host of new capabilities, SB6 effectively engages users and offers a highly visual, easily digestible look at how strategic goals are being met. It is the only all-in-one solution that tracks work and risk management, metric analysis and innovation, reflecting our vision of making strategic planning and execution seamless and successful.”

Effectively communicating strategy throughout the organization and translating that communication into action has long been problematic for organizations. Less than one-third of leaders responsible for executing strategy within the organization could list three of their company’s strategic priorities, and only 14% of employees understand their company’s strategy. To address this, StrategyBlocks integrates all facets of strategic planning into one, highly visual platform, empowering companies to have better communication, easier reporting and more agility in strategic planning.

SB6’s newest feature, StrategyBlocks Ideas, empowers users to easily share their thoughts for strategic improvements with the entire team, review others’ Ideas and follow progress, compare different Ideas and approve Ideas for integration into the overall strategic plan. Ideas integrates with StrategyBlocks’ block scheduling features, allowing users to efficiently estimate project duration, allocate workload based on availability and manage the delivery schedule in an intuitive, visually compelling way.

“Strategic planning has become more essential than ever given the rapidly-changing global economic situation. StrategyBlocks provides us with the ability to respond and quickly adjust our plan, and the new Ideas feature will allow our entire team to contribute, provide feedback and seamlessly integrate changes,” said Angie Thiessen, Project Portfolio Manager, City of Kelowna, British Columbia, Canada. “We continue to be impressed with the intuitive nature of the platform, further enhanced by this redesign, and are glad we’ve incorporated StrategyBlocks into our organization.”

In addition to StrategyBlocks Ideas, the StrategyBlocks interface has undergone a visual redesign to enhance the overall experience. This includes a reorganization of the main menu to provide a clear path for users to follow as well as the addition of a new Homepage. The homepage displays a user’s most frequently used assets, divided into several key panes:

  • Object Pane: displays items owned or managed by the user
  • Actions Pane: shows items that may require a user’s attention
  • Previews Pane: displays more information about a selected object
  • News Pane: provides updates to any recent changes to objects owned, followed or managed by the user.

Additional panes can be configured, including:

  • Blocks Pane: shows work to be done
  • Metrics Pane: focuses on outcomes to monitor
  • Risks Pane: for hazard assessment
  • Dashboards: for reports to be compiled
  • Bookmarks: shows favorited items

The new soft blue interface and color palette, taken in conjunction with the reorganized navigation menu, keeps users’ attention focused on the center of the screen instead of being lost in a complex interface. Users can then interact more quickly with StrategyBlocks to share updates on delivery progress, monitor metrics or risks and check the status of their Ideas.

About StrategyBlocks

StrategyBlocks is the leading online strategic management and strategy planning software for enterprise communication, collaboration and reporting. Its SaaS-based platform, now in Version 6, is highly adaptable, visually creative and seamlessly integrates with other business software. StrategyBlocks allows businesses to quickly implement a fully integrated solution that delivers strategic planning, improved communication, seamless ideation and real-time execution capabilities across the entire organization.

Headquartered in Auckland, New Zealand, with additional offices in Wellington and London, StrategyBlocks is a privately held company. To stay up to date with the latest in Strategic Execution Management, read our blog, and follow us on Twitter, Facebook and YouTube.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Natalee Gibson
Songue PR for StrategyBlocks
natalee@songuepr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye